Document › Details

Illumina, Inc.. (5/15/19). "Press Release: Illumina Files Patent Infringement Suit against BGI in Denmark". San Diego, CA.

Region Region Denmark
Organisations Organisation Illumina Inc. (Nasdaq: ILMN)
  Group Illumina (Group)
  Organisation 2 BGI Europe A/S (BGI Copenhagen)
  Group BGI (CN) (Group)
Products Product MGISeq-2000 sequencing system
  Product 2 reagents (bio/biochemical)
Person Person Dadswell, Charles (Illumina 201604 SVP + General Counsel)
     


Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark.

“As we have previously stated, Illumina will continue to vigorously protect our patented technology and file patent suits where appropriate when our patents are infringed,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.

The complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 3 002 289 B1. This patent covers Illumina’s proprietary sequencing-by-synthesis chemistry. The complaint also alleges that BGI’s use of the MGISEQ mark infringes Illumina’s registered EU Trademark No. 8972127 for the MISEQ name.

Earlier this year, Illumina filed a patent infringement suit against BGI Group’s subsidiary, Latvia MGI Tech SIA, in the Düsseldorf Regional Court in Germany. That complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 1 530 578 B1.


About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


Illumina, Inc.

Investors:
Jacquie Ross, CFA
+1-858-255-5243
IR@illumina.com

or

Media:
Eric Endicott
858-882-6822
pr@illumina.com

or

Media – Europe:
Karen Birmingham
+44(0) 7500105665
kbirmingham@illumina.com

   
Record changed: 2019-05-23

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Illumina (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top